- In the United States, vaccine production and distribution numbers remain encouraging. As of mid-March 2021, the potential for approximately 700 million doses being made available by the end of the summer season may be underappreciated by markets.
- According to Janasiewicz, there is a difference between inflation risk and reflation as a product of a return to more normalized economic growth. Robust fiscal aid and monetary policy support do not guarantee immediate risk of runaway inflation. By contrast, market data suggests that inflation is normalizing as the pandemic recovery continues.
- While sectors of the economy more sensitive to pandemic factors are seeing some price increases, less sensitive sectors are seeing prices weaken. Additionally, there is evidence that significant slack in the US labor market remains. Although the recovery is continuing, data suggests the US labor force participation rate remains depressed.
This material is provided for informational purposes only and should not be construed as investment advice.
The views and opinions expressed are as of March 2021 and may change based on market and other conditions. Unless otherwise noted, the opinions of the speakers provided are not necessarily those of Natixis Investment Managers or any of its affiliates.
There can be no assurance that developments will transpire as forecasted. Actual results may vary.
Performance data discussed represents past performance and is no guarantee of, and not necessarily indicative of, future results.
Provided by Natixis Distribution, L.P., 888 Boylston St., Boston, MA 02199. Natixis Investment Managers includes all of the investment management and distribution entities affiliated with Natixis Distribution, L.P. and Natixis Investment Managers S.A.